Literature DB >> 33406727

Polymorphism Analysis of pfmdr1 and pfcrt from Plasmodium falciparum Isolates in Northwestern Nigeria Revealed the Major Markers Associated with Antimalarial Resistance.

Ruqayya Adam1, Muhammad M Mukhtar2, Umar F Abubakar3, Hajara A Damudi2, Abdullahi Muhammad4,5, Sulaiman S Ibrahim2,5.   

Abstract

Suspicion of failure in the effectiveness of artemisinin-based combination therapies (currently the first-line treatment of malaria, worldwide) is leading to the unofficial use of alternative antimalarials, including chloroquine and sulfadoxine/pyrimethamine, across northern Nigeria. To facilitate evidence-based resistance management, antimalarial resistance mutations were investigated in Plasmodium falciparum multidrug resistance-1 (pfmdr1) and chloroquine resistance transporter (pfcrt), in isolates from Kano, northwestern Nigeria. Out of the 88 samples genotyped for pfmdr1N86Y mutation using PCR/restriction fragment length polymorphism, one sample contained the 86Y mutation (86Yfrequency = 1.14%). The analysis of 610 bp fragments of pfmdr1 from 16 isolates revealed two polymorphic sites and low haplotype diversity (Hd = 0.492), with only 86 Y mutations in one isolate, and 184 F replacements in five isolates (184Ffrequency = 31.25%). The analysis of 267 bp fragments of pfcrt isolates revealed high polymorphism (Hd = 0.719), with six haplotypes and seven non-synonymous polymorphic sites. Eleven isolates (61.11%) were chloroquine-resistant, CQR (C72V73I74E75T76 haplotype), two of which had an additional mutation, D57E. An additional sequence was CQR, but of the C72V73M74E75T76 haplotype, while the rest of the sequences (33.33%) were chloroquine susceptible (C72V73M74N75K76 haplotype). The findings of these well characterized resistance markers should be considered when designing resistance management strategies in the northwestern Nigeria.

Entities:  

Keywords:  Nigeria; Plasmodium falciparum; mutation, antimalarial; pfcrt; pfmdr1; resistance

Year:  2021        PMID: 33406727      PMCID: PMC7838797          DOI: 10.3390/diseases9010006

Source DB:  PubMed          Journal:  Diseases        ISSN: 2079-9721


  41 in total

1.  Pfcrt haplotypes and the evolutionary history of chloroquine-resistant Plasmodium falciparum.

Authors:  Gauri Awasthi; Godavarthi Bhogendra Krishna Satya Prasad; Godavarthi Bhogendra Krishna Satya; Aparup Das
Journal:  Mem Inst Oswaldo Cruz       Date:  2012-02       Impact factor: 2.743

2.  Kelch 13 propeller gene polymorphism among Plasmodium falciparum isolates in Lagos, Nigeria: Molecular Epidemiologic Study.

Authors:  Uche Igbasi; Wellington Oyibo; Sunday Omilabu; Hong Quan; Shen-Bo Chen; Hai-Mo Shen; Jun-Hu Chen; Xiao-Nong Zhou
Journal:  Trop Med Int Health       Date:  2019-06-17       Impact factor: 2.622

3.  The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin.

Authors:  M T Duraisingh; P Jones; I Sambou; L von Seidlein; M Pinder; D C Warhurst
Journal:  Mol Biochem Parasitol       Date:  2000-04-30       Impact factor: 1.759

4.  In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria.

Authors:  O A Folarin; C Bustamante; G O Gbotosho; A Sowunmi; M G Zalis; A M J Oduola; C T Happi
Journal:  Acta Trop       Date:  2011-09-06       Impact factor: 3.112

5.  A molecular marker for chloroquine-resistant falciparum malaria.

Authors:  A Djimdé; O K Doumbo; J F Cortese; K Kayentao; S Doumbo; Y Diourté; D Coulibaly; A Dicko; X Z Su; T Nomura; D A Fidock; T E Wellems; C V Plowe
Journal:  N Engl J Med       Date:  2001-01-25       Impact factor: 91.245

6.  Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases.

Authors:  Nnennaya Anthony Ajayi; Kingsley Nnanna Ukwaja
Journal:  Rev Soc Bras Med Trop       Date:  2013 Jul-Aug       Impact factor: 1.581

7.  Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Mansour Fall; Eric Baret; Cheikhou Camara; Aminata Nakoulima; Bakary Diatta; Khadidiatou Ba Fall; Pape Saliou Mbaye; Yaya Diémé; Raymond Bercion; Boubacar Wade; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

8.  Asymptomatic malaria infections and Pfmdr1 mutations in an endemic area of Nigeria.

Authors:  Titilope M Dokunmu; Cynthia U Adjekukor; Omolara F Yakubu; Adetutu O Bello; Jarat O Adekoya; Olugbenga Akinola; Emmanuel O Amoo; Abiodun H Adebayo
Journal:  Malar J       Date:  2019-06-27       Impact factor: 2.979

9.  Correlation of molecular markers, Pfmdr1-N86Y and Pfcrt-K76T, with in vitro chloroquine resistant Plasmodium falciparum, isolated in the malaria endemic states of Assam and Arunachal Pradesh, Northeast India.

Authors:  Sandeep Kumar Shrivastava; Ravi Kumar Gupta; Jagdish Mahanta; Mohan Lal Dubey
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

10.  Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.

Authors:  M Isabel Veiga; Satish K Dhingra; Philipp P Henrich; Judith Straimer; Nina Gnädig; Anne-Catrin Uhlemann; Rowena E Martin; Adele M Lehane; David A Fidock
Journal:  Nat Commun       Date:  2016-05-18       Impact factor: 14.919

View more
  1 in total

1.  High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia.

Authors:  Jifar Hassen; Gezahegn Solomon Alemayehu; Hunduma Dinka; Lemu Golassa
Journal:  Malar J       Date:  2022-10-07       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.